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Summary
Prompt cancer diagnosis may align UK survival with European averages. We exam-
ined the impact of route to diagnosis on survival for multiple myeloma patients
diagnosed 2012–2013 using data from our population-based patient cohort that
links to national death notifications and collects details on treatment and response
(n = 441). Emergency presentation was associated with advanced disease and poorer
outcomes, and was the commonest route to diagnosis (281%) followed by General
Practitioner urgent (190%) and two-week wait (172%) referrals. CRAB (elevated
Calcium, Renal failure, Anaemia, Bone lesions) distribution varied by route
(P < 0001), with patients with emergency presentations most likely to have ≥2 fea-
tures and significantly worse survival (log-rank test v2 = 138, P = 00002).
Keywords: multiple myeloma, route to diagnosis, clinical characteristics,
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Estimates suggest that each year in Britain, 6600–7500 pre-
mature cancer deaths could be prevented if survival matched
European averages (Abdel-Rahman et al, 2009). Around a
quarter of these “avoidable” deaths are attributable to
haematological malignancies, with multiple myeloma (MM)
accounting for almost half. Earlier diagnosis has been identi-
fied as one factor likely to improve cancer outcomes (Thom-
son & Forman, 2009), and a series of interventions have
been introduced into UK practice to promote this, including
referral guidance to facilitate identification of cancer symp-
toms in primary care and a suspected cancer referral pathway
(“two-week wait”) (Department of Health, 2000; NICE,
2005). Whilst the former has expedited diagnosis of many
cancers, average times for MM have increased (Neal et al,
2014).
An estimated 4,300 people are diagnosed with MM annu-
ally in the UK www.hmrn.org/statistics/incidence. Presenting
symptoms are often vague and include musculoskeletal pain
and tiredness; and patients are more likely than those with
other cancers to have three or more General Practitioner
(GP) visits before a secondary care referral is initiated (Lyrat-
zopoulos et al, 2012; Howell et al, 2013). Delayed diagnosis
of MM is associated with increased risk of complications
(bone disease, anaemia and renal failure) and poorer survival
(Kariyawasan et al, 2007; Friese et al, 2009). MM is also
more likely than other cancers to be diagnosed after emer-
gency presentation, a route considered a crude indicator of
delay and associated with poorer outcomes (Elliss-Brookes
et al, 2012). This paper examines the impact of route to
diagnosis on MM survival and clinical complications.
Patients and methods
The study is set within the Haematological Malignancy
Research Network (HMRN: www.hmrn.org), a UK popula-
tion-based cohort instigated in 2004 to generate ‘real world’
data for research and clinical purposes (www.hmrn.org/publi
cations/papers). HMRN covers a population of around four
million, with clinical care in the area adhering to national
guidance (Smith et al, 2011). All diagnoses of haematological
malignancy (>2200 annually) are made and coded using
the latest World Health Organization (WHO) oncology
classification (Swerdlow et al, 2016) by a single integrated
haematopathology laboratory (the Haematological Malignancy
Diagnostic Service: www.hmds.info). Following diagnosis, a
core dataset is routinely abstracted from patients’ medical
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records. For MM this includes diagnostic imaging and blood
tests, with complications and prognostic risk being assessed
using components of the CRAB (elevated Calcium, Renal fail-
ure, Anaemia, Bone lesions) criteria (Rajkumar et al, 2014)
and the International Staging System (ISS) (Greipp et al,
2005). With Section 251 support, all HMRN patients are
tracked through clinical systems and linked to nationwide
information on deaths.
For the present study, core data on myeloma patients
diagnosed 1 July 2012 to 31 December 2013 were supple-
mented with information on routes to diagnosis. This
included documentation of all referrals from the time the
patient first presented to hospital with potential MM symp-
toms to diagnosis, defined as the date HMDS received the
diagnostic sample. Data abstracted for each referral were:
date/type of referral, clinical speciality referred from/to, and
date of first appointment. Referral categories were based on
the UK’s National Cancer Intelligence Network (NCIN)
study (Table SI).
Survival (from date of diagnosis) was calculated with stan-
dard time-to-event analyses, and the program strel (v1.2.7;
http://www.lshtm.ac.uk/ncde/cancersurvival/tools.htm) was used
to estimate relative survival. Age and sex-specific background
mortality rates were obtained from national life tables (Alle-
mani et al, 2015), and all analyses were undertaken in Stata 14
(www.stata.com).
Results
With a median diagnostic age of 742 years, 441 patients
were diagnosed with MM during the study period. Overall,
emergency presentation was the commonest route to diagno-
sis (281%, n = 124). Around two-thirds of patients using
the emergency route (n = 79) had been referred to hospital
by a GP, either via Accident and Emergency (A&E) or a
direct ward-admission. Of the 45 without prior GP contact,
34 self-referred to A&E or arrived via the actions of family
members, nursing home staff, emergency services or the gen-
eral public; and the remainder were referred from other hos-
pital specialities (e.g. imaging, physiotherapy). After
emergency, the next most frequent routes were GP urgent
(n = 84, 190%), GP two-week wait (n = 76, 172%), GP
routine (n = 56, 127%) and hospital consultant-to-consul-
tant (n = 41, 93%).
Overall, 60 patients (136%) had no referral route
recorded, either because they were already being monitored
by haematology (commonly for monoclonal gammopathy
of undetermined significance, MGUS) (n = 39, 88%) or
because no details were documented in their hospital
records (n = 21, 48%). Demographic and clinical charac-
teristics of the remaining 381 (864%) patients with a
referral route are presented in Table I. According to CRAB
criteria, 114 (299%) of these patients were asymptomatic
at diagnosis (score: zero), 139 (365%) had one CRAB fea-
ture and 125 (328%) had two or more. CRAB could not
be calculated for 3 patients: one (aged >80 years) died
from other causes, one (aged >80 years) opted for no
tests/treatment and died at home, and another (aged
>90 years) died from kidney disease. CRAB distributions
varied markedly with referral route (P < 0001), with
patients presenting as an emergency being the most likely
to have a CRAB score ≥2 (n = 70, 565%) and the least
likely to have a score of zero (n = 11, 89%). Conversely,
patients with routine referrals were least likely to have a
CRAB ≥2 (n = 6, 107%) and most likely to be asymp-
tomatic (n = 28, 500%). Findings for ISS showed similar
variations, with ISS III (the most clinically advanced dis-
ease) being most commonly seen among emergency pre-
sentations (n = 48, 511%). ISS could not be calculated for
70 (18.4%) patients, largely because beta2 microglobulin
(b2M) was not measured.
Information on haematology referrals and first-line man-
agement is also presented in Table I. Of two-week wait refer-
rals (to any clinical speciality), around 9 out of every 10 (68/
76) were sent directly to haematology, as were around three-
quarters of those entering secondary care by all other routes
except emergency. Patients with routine referrals tended to
have fewer risk factors at presentation and around half were
initially managed by observation. In contrast, 774% of emer-
gency presentations received first-line chemotherapy/radio-
therapy and 145% were managed with supportive/palliative
intent – both proportions being higher than any other diag-
nostic route.
Importantly, these differences translate into marked varia-
tions in outcome, with the overall and relative survival of
patients with an emergency route being significantly worse
than those presenting via other routes (Fig 1). As might be
expected, the impact on survival is immediate; the overall
survival (OS) and relative survival (RS) estimates of patients
presenting as an emergency diverging markedly from that of
other patients within 3 months of diagnosis: the 1 year RS
estimates being 726% (95% Confidence Interval (CI) 629–
802%) and 886% (95% CI 837–921%) for emergency and
non-emergency presentation respectively (log-rank test
v2 = 138, P = 00002).
Discussion
Multiple myeloma patients diagnosed via the emergency
route were more likely to have clinically advanced disease,
be managed with first-line chemotherapy/radiotherapy or
supportive/palliative intent and have the poorest survival.
Conversely, around a third of patients presenting by other
routes had asymptomatic disease and were initially man-
aged with observation. The greatest impact on mortality
was seen within the first 6 months of diagnosis, during
which time around 1 in 4 patients who presented as an
emergency died compared to less than 1 in 10 of those
presenting via other routes. That these patients had more
advanced/aggressive disease was evidenced by their
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significantly greater need for chemotherapy/radiotherapy as
first-line treatment. A small proportion of emergency pre-
sentations were, however solely observed, and while this
may appear counterintuitive, these patients were mostly
diagnosed incidentally during investigations for other seri-
ous co-morbidities.
Determining when to monitor, actively investigate, or refer
patients to hospital can prove challenging in primary care,
particularly for cancers like MM that can present with vague
symptoms and insidious onset. Nonetheless, GPs played a
significant role in referrals, initiating almost two-thirds of
emergency presentations and a large proportion of non-
emergency referrals to haematology, suggesting prior identifi-
cation of blood-related abnormalities. Similarly, 90% of all
GP two-week wait referrals were direct to haematology,
implying suspicion of haematological malignancy.
This is the first study to use secondary care data alongside
demographic and clinical details to examine routes to diag-
nosis of MM. Major strengths include a large well-defined
population-based catchment area, completeness of case ascer-
tainment, detailed follow-up and world-class diagnostics.
CRAB scores were largely complete, although ISS was missing
for a fifth of patients because b2M was not always measured,
particularly in older patients and those with a prior diagnosis
of MGUS.
Detailed data of the type presented here are not available
elsewhere for direct comparison. The UK NCIN study
(Elliss-Brookes et al, 2012), based on Hospital Episode
Table I. Referral route by demographic and clinical characteristics: HMRN myeloma diagnoses July 2012 to December 2013.
Referral route
Emergency Two-week wait GP urgent Routine Consultant
N (%) N (%) N (%) N (%) N (%)
Total 124 (1000) 76 (1000) 84 (1000) 56 (1000) 41 (1000)
Sex
Males 70 (565) 41 (539) 47 (560) 35 (625) 27 (659)
Females 54 (435) 35 (461) 37 (440) 21 (375) 14 (341)
Age at diagnosis (years)
Median (IQR) 737 (654–795) 747 (641–809) 719 (642–802) 745 (687–817) 743 (673–787)
CRAB features
0 11 (89) 27 (365) 35 (417) 28 (500) 13 (317)
1 42 (341) 32 (432) 29 (345) 22 (393) 14 (341)
≥2 70 (565) 15 (197) 20 (238) 6 (107) 14 (341)
Unknown 1 2 0 0 0
Hypercalcaemia
Yes 22 (177) 5 (66) 1 (12) 3 (54) 5 (122)
No 102 (823) 71 (934) 83 (988) 53 (946) 36 (878)
Renal insufficiency
Yes 43 (347) 3 (39) 9 (107) 2 (36) 9 (220)
No 81 (653) 73 (961) 75 (893) 54 (964) 31 (780)
Anaemia
Yes 62 (500) 18 (237) 25 (298) 12 (214) 15 (366)
No 62 (500) 58 (763) 59 (702) 44 (786) 25 (634)
Bone disease
Yes 85 (697) 41 (554) 35 (417) 19 (345) 21 (512)
No 37 (303) 33 (446) 49 (583) 36 (655) 20 (488)
Unknown 2 2 0 1 0
ISS
I 9 (96) 28 (418) 21 (304) 19 (413) 9 (257)
II 37 (394) 21 (313) 26 (377) 20 (435) 9 (257)
III 48 (511) 18 (269) 22 (319) 7 (152) 17 (486)
Unknown 30 9 15 10 6
First referral to haematology 0 (00) 68 (895) 63 (750) 41 (732) 31 (756)
First line management
Chemo/radiotherapy 96 (774) 45 (592) 49 (583) 24 (429) 24 (585)
Observation 10 (81) 26 (342) 26 (310) 28 (500) 15 (366)
Supportive/palliative 18 (145) 5 (66) 9 (107) 4 (71) 2 (49)
CRAB, elevated Calcium, Renal failure, Anaemia, Bone lesions; GP, General Practitioner; HMRN, Haematological Malignancy Research Network;
IQR, interquartile range; ISS, International Staging System.
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Statistics, reported a higher proportion of emergency presen-
tations and fewer two-week waits; similar proportions of
routine/urgent GP referrals combined; and poorer 1 year RS
(51%, 95% CI 490–530). These differences may reflect the
survival advantages of new treatments, or the way the date of
diagnosis (e.g. report date) was assigned in our cohort com-
pared to later dates often used in national data (e.g. first
treatment date).
Our findings highlight the potential benefits of expedit-
ing MM diagnosis and minimising emergency presenta-
tions. This may be achieved through raising awareness
about MM, both in health settings and among the general
public. Furthermore, a better understanding of events
in primary care would facilitate the development and test-
ing of evidence-based interventions to prevent emergency
presentation.
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